drugset / Trial / NCT00434174
Safety of Everolimus and Pemetrexed in Lung Cancer Patients
Non-randomizedSingle-groupOpen-labelTreatment
Summary
This study will evaluate the safety of everolimus in combination with pemetrexed when used as treatment in patients with non small cell lung cancer.
Timeline
- Start
- 2006-12
- Primary completion
- 2010-12
- Completion
- 2010-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Everolimus | Small molecule | 2.5 mg | — |
| Subject | Everolimus | Small molecule | 5 mg | — |
| Subject | Everolimus | Small molecule | 7.5 mg | — |
| Subject | Everolimus | Small molecule | 10 mg | — |
| Subject | Pemetrexed | Small molecule | 500 mg/m2 | Intravenous |